StonvexLoading…
StonvexStonvexStonvexCore line items from BIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $592.10M | $2.58B | $1.89B | $1.24B |
Operating Income | $34.10M | $47.20M | $166.10M | $100.80M |
Net Income | $-527.10M | $759.90M | $39.90M | $317.80M |
EPS (Diluted) | $-19.55 | $27.85 | $1.46 | $13.84 |
Total Assets | $9.79B | $10.58B | $9.70B | $10.21B |
Total Liabilities | $2.94B | $3.12B | $2.96B | $3.09B |
Cash & Equivalents | $507.20M | $529.80M | $395.80M | $369.30M |
Free Cash Flow OCF − CapEx | $78.10M | $374.60M | $255.50M | $166.30M |
Shares Outstanding | 26.96M | 27.28M | 27.37M | 27.59M |